Amneal taps former Teva CEO to head up commercial ops
Amneal Pharmaceuticals and Impax Laboratories on Tuesday announced that Andrew Boyer, 52, has joined Amneal as executive vice president, commercial operations and is expected to serve in the same capacity for the new Amneal following the consummation of the combination of Amneal with Impax. Boyer most recently served as president and CEO of North America Generics, Teva Pharmaceuticals.
"We are pleased that Andy has joined Amneal and will be leading our commercial organization," Chirag Patel, co-CEO and chairman, Amneal Pharmaceuticals, said. "Andy is an accomplished executive with more than 20 years of pharmaceutical experience architecting commercial strategies designed to capitalize on changing customer needs and market opportunities. His addition further enhances our current leadership team as well as the proposed leadership team for the new Amneal."
Boyer will work closely with Chirag and Chintu Patel, Amneal's current co-CEOs, and Rob Stewart, president of Amneal and the future CEO of the new Amneal, headquartered in Bridgewater, N.J., to further enhance its business in preparation for the pending combination with Impax, which is currently expected to occur in the first half of 2018.
Prior to joining Teva, Boyer was senior vice president sales and marketing for the U.S. Generics Division at Allergan since September of 2006. Boyer joined Allergan in 1998 as associate director marketing in generics. Before joining Allergan, Boyer served as national accounts manager for Lederle/American Cyanamid as well as marketing manager for Barr Laboratories.
Boyer received his bachelor's degree in Business Administration and Management from State University of New York at Albany.
"We are pleased that Andy has joined Amneal and will be leading our commercial organization," Chirag Patel, co-CEO and chairman, Amneal Pharmaceuticals, said. "Andy is an accomplished executive with more than 20 years of pharmaceutical experience architecting commercial strategies designed to capitalize on changing customer needs and market opportunities. His addition further enhances our current leadership team as well as the proposed leadership team for the new Amneal."
Boyer will work closely with Chirag and Chintu Patel, Amneal's current co-CEOs, and Rob Stewart, president of Amneal and the future CEO of the new Amneal, headquartered in Bridgewater, N.J., to further enhance its business in preparation for the pending combination with Impax, which is currently expected to occur in the first half of 2018.
Prior to joining Teva, Boyer was senior vice president sales and marketing for the U.S. Generics Division at Allergan since September of 2006. Boyer joined Allergan in 1998 as associate director marketing in generics. Before joining Allergan, Boyer served as national accounts manager for Lederle/American Cyanamid as well as marketing manager for Barr Laboratories.
Boyer received his bachelor's degree in Business Administration and Management from State University of New York at Albany.